NCT00203164View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

September 30, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

rasagiline mesylate

rasagiline mesylate 1 mg oral once daily

Trial Locations (6)

11040

Long Island Jewish Medical Center, New Hyde Park

14642

University of Rochester, Rochester

19107

Pennsylvania Hospital, Philadelphia

60612

Rush - Presbyterian St. Luke's Medical Center, Chicago

68131

Creighton University, Omaha

93720

Margolin Brain Institute, Fresno

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203164 - Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter